Randomised beta-carotene supplementation and incidence of cancer and cardiovascular disease in women: is the association modified by baseline plasma level?

Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 900 Commonwealth Avenue East, Boston, Massachusetts, MA 02215, USA.
British Journal of Cancer (Impact Factor: 4.82). 04/2002; 86(5):698-701. DOI: 10.1038/sj.bjc.6600147
Source: PubMed

ABSTRACT In a nested case-control study of 513 women with cancer; 130 with cardiovascular disease and equal numbers of controls, we found no effect of randomised beta-carotene on risk of cancer or cardiovascular disease within any quartile of baseline plasma beta-carotene, nor was there a trend across quartiles (P for trend 0.15 and 0.62, respectively).

  • [Show abstract] [Hide abstract]
    ABSTRACT: Smoking prevention and cessation remain the primary methods of reducing the incidence of lung cancer. The limited success of efforts towards smoking cessation have led to increasing interest in the role of nutrition in lung cancer prevention. One class of nutrients that has attracted attention as potential chemopreventive agents is the carotenoids, especially beta-carotene, due to their antioxidant properties. In vitro, carotenoids exert antioxidant functions and inhibit carcinogen-induced neoplastic transformation, inhibit plasma membrane lipid oxidation, and cause upregulated expression of connexin 43. These in vitro results suggest that carotenoids have intrinsic cancer chemopreventive action in humans. Many cohort and case-control study data have shown an inverse relationship between fruit and vegetable consumption and lung cancer, although several more recent studies have cast doubt on these findings. Different effects of various dietary nutrients on lung cancer risk have been observed. Several prospective intervention trials were undertaken to examine the effect of supplementation on the risk of lung cancer. Some of these studies demonstrated an increased incidence and mortality from lung cancer in those receiving supplementation. Many hypotheses have emerged as to the reasons for these findings.
    Seminars in Oncology 03/2003; 30(1):86-93. · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This meta-analysis aimed to investigate the effects of beta-carotene supplements alone on cancer prevention as reported by randomized controlled trials (RCTs). We searched PubMed, EMBASE, and CENTRAL. Among the 848 articles searched, 6 randomized controlled trials, including 40,544 total participants, 20,290 in beta-carotene supplement groups, and 20,254 in placebo groups, were included in the final analysis. In a meta-analysis of 6 RCTs, beta-carotene supplements had no preventive effect on either cancer incidence [relative risk (RR) = 1.08, 95% confidence interval (CI) = 0.99-1.18] or cancer mortality (RR = 1.00, 95% CI = 0.87-1.15). Similar findings were observed in both primary prevention trials and secondary prevention trials. Subgroup analyses by various factors revealed no preventive effect of beta-carotene supplementation on cancer prevention and that it significantly increased the risk of urothelial cancer, especially bladder cancer (RR = 1.52, 95% CI = 1.03-2.24) and marginally increased the risk of cancer among current smokers (RR = 1.07, 95% CI = 0.99-1.17). The current meta-analysis of RCTs indicated that there is no clinical evidence to support the overall primary or secondary preventive effect of beta-carotene supplements on cancer. The potential effects, either beneficial or harmful, of beta-carotene supplementation on cancer should not be overemphasized.
    Nutrition and Cancer 11/2011; 63(8):1196-207. · 2.70 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antioxidant vitamins are thought to play a role in atherosclerosis. Supplementation of these nutrients has been explored as a means of reducing cardiovascular morbidity and mortality. To assess the evidence of the effectiveness of vitamin supplementation, specifically vitamins A, C, and E; beta-carotene; folic acid; antioxidant combinations; and multivitamin supplements, in preventing cardiovascular disease. Cochrane Controlled Trials Registry and MEDLINE (1966 to September 2001), reference lists, and experts. The researchers selected English-language reports of randomized trials and cohort studies that assessed vitamin supplementation in western populations and reported incidence of or death from cardiovascular events. They also included reports of good- or fair-quality clinical trials of primary and secondary prevention and good- or fair-quality prospective cohort studies. Studies that examined only dietary nutrients or did not provide separate estimates for supplements were not included. Two reviewers abstracted descriptive information and data on cardiovascular outcomes and mortality from included studies. The researchers assessed study quality using predetermined criteria. Evidence tables were constructed to summarize data from included studies. The researchers summarized the strength, level, and quality of the overall evidence for the effectiveness of each of the vitamin supplements in preventing or treating cardiovascular disease. Some good-quality cohort studies have reported an association between the use of vitamin supplements and lower risk for cardiovascular disease. Randomized, controlled trials of specific supplements, however, have failed to demonstrate a consistent or significant effect of any single vitamin or combination of vitamins on incidence of or death from cardiovascular disease. Understanding the sources of these differences will permit researchers to better analyze the cohort study data and to better design long-term clinical trials.
    Annals of internal medicine 08/2003; 139(1):56-70. · 16.10 Impact Factor


Available from